PLANDAI BIOTECHNOLOGY INC - PLPL STOCK NEWS

ByoPlanet, a subsidiary of Plandai Biotechnology, has established a one-year distribution agreement with Merck Animal Health to distribute Merck's Armatrex antimicrobial solution in the animal health market. The partnership aims to provide customers with advanced antimicrobial solutions and leverage the strengths of both companies. Armatrex offers a comprehensive solution to combat harmful pathogens and protect animals from diseases. ByoPlanet will be responsible for distribution and marketing, while Merck Animal Health brings its reputation for excellence in animal health.

Plandai Biotechnology, Inc. announces the completion of a share exchange agreement with ByoPlanet. ByoPlanet will become a wholly-owned subsidiary of PLPL. Rick O'Shea, CEO of ByoPlanet, will become CEO of Plandai.

Plandai Biotechnology, Inc. (OTC PINK:PLPL) has announced a binding memorandum of understanding to acquire Good Salt, LLC, which includes the assets and operations of ByoPlanet International and Clean Republic. ByoPlanet specializes in electrostatic cleaning technology that improves disinfection efficiency and reduces chemical usage. This acquisition aligns with Plandai's new strategic direction, focusing on health technology innovation. Additionally, Plandai is preparing for a potential up listing, having completed audits for its fiscal years ending June 30, 2022, and June 30, 2021. The company plans to change its name to ByoPlanet, Inc. and seek a new trading symbol, pending regulatory approval.

Plandai Biotechnology, Inc. (OTC: PLPL) has terminated its asset acquisition agreement with EV Hotel Corp. without incurring any penalties. This decision was mutually agreed upon by both parties. Additionally, the Company has completed a two-year independent audit of its financial statements, which will inform future disclosures and ongoing merger efforts. Plandai seeks to generate shareholder value by merging with entities offering growth opportunities.